Telos Capital Management Inc. Increases Stake in Eli Lilly and Company (NYSE:LLY)

Telos Capital Management Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 23.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,987 shares of the company’s stock after buying an additional 371 shares during the quarter. Telos Capital Management Inc.’s holdings in Eli Lilly and Company were worth $1,534,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. AMF Tjanstepension AB increased its position in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after acquiring an additional 176,552 shares during the period. Brendel Financial Advisors LLC increased its holdings in Eli Lilly and Company by 5.9% during the 3rd quarter. Brendel Financial Advisors LLC now owns 2,192 shares of the company’s stock valued at $1,942,000 after purchasing an additional 122 shares during the period. B & T Capital Management DBA Alpha Capital Management raised its position in Eli Lilly and Company by 748.9% during the 3rd quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,073 shares of the company’s stock valued at $2,722,000 after purchasing an additional 2,711 shares during the last quarter. Strategic Advisors LLC lifted its holdings in Eli Lilly and Company by 1.7% in the 3rd quarter. Strategic Advisors LLC now owns 1,633 shares of the company’s stock worth $1,447,000 after buying an additional 28 shares during the period. Finally, Boston Common Asset Management LLC grew its position in shares of Eli Lilly and Company by 77.5% in the 3rd quarter. Boston Common Asset Management LLC now owns 18,563 shares of the company’s stock worth $16,446,000 after buying an additional 8,106 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Barclays decreased their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Bank of America reaffirmed a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Stock Up 0.9 %

Shares of Eli Lilly and Company stock opened at $878.09 on Friday. The company has a 50-day simple moving average of $788.21 and a two-hundred day simple moving average of $843.47. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $833.59 billion, a PE ratio of 94.93, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. On average, analysts anticipate that Eli Lilly and Company will post 12.85 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.68%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.